Charles River Laboratories Intl. Inc (CRL) Holdings Lifted by Pacer Advisors Inc.

Pacer Advisors Inc. grew its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 13.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,271 shares of the medical research company’s stock after purchasing an additional 2,112 shares during the quarter. Pacer Advisors Inc.’s holdings in Charles River Laboratories Intl. were worth $2,324,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Mackay Shields LLC lifted its stake in shares of Charles River Laboratories Intl. by 272.4% during the 2nd quarter. Mackay Shields LLC now owns 46,182 shares of the medical research company’s stock worth $5,184,000 after purchasing an additional 33,781 shares during the period. Rhumbline Advisers lifted its stake in shares of Charles River Laboratories Intl. by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 106,963 shares of the medical research company’s stock worth $12,008,000 after purchasing an additional 4,842 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Charles River Laboratories Intl. during the 2nd quarter worth $460,000. Cadence Capital Management LLC lifted its stake in shares of Charles River Laboratories Intl. by 7.1% during the 3rd quarter. Cadence Capital Management LLC now owns 13,142 shares of the medical research company’s stock worth $1,768,000 after purchasing an additional 873 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Charles River Laboratories Intl. during the 2nd quarter worth $212,000. 96.19% of the stock is currently owned by institutional investors.

Shares of CRL opened at $124.96 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.32 and a current ratio of 1.55. Charles River Laboratories Intl. Inc has a twelve month low of $96.70 and a twelve month high of $139.72. The firm has a market capitalization of $6.01 billion, a P/E ratio of 21.07, a PEG ratio of 1.76 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a return on equity of 25.08% and a net margin of 6.39%. The company had revenue of $585.30 million for the quarter, compared to analyst estimates of $567.58 million. During the same period last year, the company posted $1.30 earnings per share. The firm’s revenue was up 26.1% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories Intl. Inc will post 5.93 EPS for the current year.

In other Charles River Laboratories Intl. news, Chairman James C. Foster sold 1,977 shares of the firm’s stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $129.11, for a total value of $255,250.47. Following the transaction, the chairman now directly owns 267,676 shares of the company’s stock, valued at $34,559,648.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Ross Smith sold 1,866 shares of the firm’s stock in a transaction dated Monday, November 12th. The shares were sold at an average price of $134.49, for a total value of $250,958.34. Following the completion of the transaction, the insider now directly owns 12,341 shares in the company, valued at $1,659,741.09. The disclosure for this sale can be found here. Insiders sold 30,639 shares of company stock worth $4,142,794 over the last three months. 2.10% of the stock is currently owned by corporate insiders.

Several research analysts recently weighed in on CRL shares. Robert W. Baird increased their target price on Charles River Laboratories Intl. from $133.00 to $141.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Raymond James increased their target price on Charles River Laboratories Intl. from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 8th. Credit Suisse Group cut their target price on Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 21st. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Tuesday, August 28th. Finally, Royal Bank of Canada set a $147.00 target price on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $132.06.

TRADEMARK VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/12/16/charles-river-laboratories-intl-inc-crl-holdings-lifted-by-pacer-advisors-inc.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit